Search Results - Ruth Plummer
Ruth Plummer
Elizabeth Ruth Plummer is a British oncologist and academic. She is a Professor of Experimental Cancer Medicine at Newcastle University and an oncologist specialising in treating patients with melanoma. Based in Newcastle, she directs the Sir Bobby Robson Cancer Trials Research Centre, set up by the Sir Bobby Robson Foundation to run early-stage clinical trials.v Plummer and the Newcastle team won a 2010 Translational Cancer Research Prize from Cancer Research UK for work using rucaparib to treat ovarian cancer. Plummer was elected as a fellow of the UK's Academy of Medical Sciences in 2018. Provided by Wikipedia- Showing 1 - 11 results of 11
-
1
A hybrid machine learning approach for the personalized prognostication of aggressive skin cancers by Tom W. Andrew, Mogdad Alrawi, Ruth Plummer, Nick Reynolds, Vern Sondak, Isaac Brownell, Penny E. Lovat, Aidan Rose, Sophia Z. Shalhout
Published in npj Digital Medicine (2025-01-01)Get full text
Article -
2
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study proto... by Sarah Johnson, Geoff Shenton, Ruth Plummer, Joshua Savage, Gareth J Veal, Julie Irving, Lucinda Billingham, Pamela Kearns, Daniel Slade, Tobias Menne, Britta Vormoor, Josef Vormoor
Published in BMJ Open (2022-03-01)Get full text
Article -
3
Targeting the DNA double strand break repair machinery in prostate cancer. by Fadhel S Shaheen, Pawel Znojek, Ann Fisher, Martin Webster, Ruth Plummer, Luke Gaughan, Graeme C M Smith, Hing Y Leung, Nicola J Curtin, Craig N Robson
Published in PLoS ONE (2011-01-01)Get full text
Article -
4
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu
Published in Journal for ImmunoTherapy of Cancer (2021-07-01)Get full text
Article -
5
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT by Vicky Coyle, Caroline Forde, Richard Adams, Ashley Agus, Rosemary Barnes, Ian Chau, Mike Clarke, Annmarie Doran, Margaret Grayson, Danny McAuley, Cliona McDowell, Glenn Phair, Ruth Plummer, Dawn Storey, Anne Thomas, Richard Wilson, Ronan McMullan
Published in Health Technology Assessment (2024-03-01)Get full text
Article -
6
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study by Abigail Gault, Linda Hogarth, Kristian C Williams, Alastair Greystoke, Neil Rajan, Ally Speight, Christopher A Lamb, Alison Bridgewood, Lisa-Jayne Brown-Schofield, Fiona Rayner, John D Isaacs, Jérémie Nsengimana, Christopher J Stewart, Amy E Anderson, Ruth Plummer, Arthur G Pratt
Published in BMC Cancer (2024-06-01)Get full text
Article -
7
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer by Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer
Published in npj Breast Cancer (2022-04-01)Get full text
Article -
8
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase by Sarah E. Fordham, Helen J. Blair, Claire J. Elstob, Ruth Plummer, Yvette Drew, Nicola J. Curtin, Olaf Heidenreich, Deepali Pal, David Jamieson, Catherine Park, John Pollard, Scott Fields, Paul Milne, Graham H. Jackson, Helen J. Marr, Tobias Menne, Gail L. Jones, James M. Allan
Published in Blood Advances (2018-05-01)Get full text
Article -
9
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma by Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, Andrew M Haydon
Published in Journal for ImmunoTherapy of Cancer (2022-07-01)Get full text
Article -
10
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort stu... by Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Published in EClinicalMedicine (2024-05-01)Get full text
Article -
11
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort stu... by Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, Keith T. Flaherty
Published in EClinicalMedicine (2023-11-01)Get full text
Article
